Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Biomarkers
Breast cancer
HER2
HER2-low
Pathology report
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
received:
20
07
2023
accepted:
13
09
2023
revised:
03
09
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
28
9
2023
Statut:
aheadofprint
Résumé
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The trial focused on patients with metastatic breast cancer who were classified as "HER2-low," i.e., those with immunohistochemistry (IHC) HER2 1 + or 2 + and negative in situ hybridization (ISH) results. The study revealed that treating these patients with trastuzumab deruxtecan (T-DXd) instead of the oncologist's chosen chemotherapy led to outstanding improvements in survival. This has challenged the existing binary HER2 pathological classification system, which categorized tumors as either positive (overexpression/amplification) or negative, as per the ASCO/CAP 2018 guideline reaffirmed by ASCO/CAP 2023 guideline update. Given that DB-04 excluded patients with HER2 IHC score 0 status, the results of the ongoing DB-06 trial may shed further light on the potential benefits of T-DXd therapy for these patients. Roughly half of all breast cancers are estimated to belong to the HER2-low category, which does not represent a distinct or specific subtype of cancer. Instead, it encompasses a diverse group of tumors that exhibit clinical, morphological, immunohistochemical, and molecular variations. However, HER2-low offers a distinctive biomarker status that identifies a specific therapeutic regimen (i.e., T-DXd) linked to a favorable prognosis in breast cancer. This unique association emphasizes the importance of accurately identifying these tumors. Differentiating between a HER2 IHC score 0 and score 1 + has not been clinically significant until now. To ensure accurate classification and avoid misdiagnosis, it is necessary to adopt standardized procedures, guidelines, and specialized training for pathologists in interpreting HER2 expression in the lower spectrum. Additionally, the utilization of artificial intelligence holds promise in supporting this endeavor. Here, we address the current state of the art and unresolved issues in assessing HER2-low status, with a particular emphasis on the score 0. We explore the dilemma surrounding the exclusion of HER2-zero patients from potentially beneficial therapy based on traditional HER2 testing. Additionally, we examine the clinical context, considering that DB-04 primarily involved heavily pretreated late-stage metastatic breast cancers. We also delve into emerging evidence suggesting that extrapolating HER2-low status from the original diagnosis may lead to misleading results. Finally, we provide recommendations for conducting high-quality testing and propose a standardized pathology report in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Identifiants
pubmed: 37770765
doi: 10.1007/s00428-023-03656-w
pii: 10.1007/s00428-023-03656-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
(2020) Trastuzumab deruxtecan is effective in HER2-low breast cancer. Cancer Discov 10(4):488. https://doi.org/10.1158/2159-8290.cd-rw2020-030
Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C, de Azambuja E (2021) HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel) 13:2824. https://doi.org/10.3390/cancers13112824
doi: 10.3390/cancers13112824
pubmed: 34198891
Ahn S, Woo JW, Lee K, Park SY (2020) HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 54:34–44. https://doi.org/10.4132/jptm.2019.11.03
doi: 10.4132/jptm.2019.11.03
pubmed: 31693827
Angerilli V, Galuppini F, Pagni F, Fusco N, Malapelle U, Fassan M (2021) The role of the pathologist in the next-generation era of tumor molecular characterization. Diagnostics 11:339
doi: 10.3390/diagnostics11020339
pubmed: 33670699
pmcid: 7922586
Ballard M, Jalikis F, Krings G, Schmidt RA, Chen Y-Y, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML, Allison KH (2017) ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol 30:227–235. https://doi.org/10.1038/modpathol.2016.175
doi: 10.1038/modpathol.2016.175
pubmed: 27739440
Bianchi S, Caini S, Paglierani M, Saieva C, Vezzosi V, Baroni G, Simoni A, Palli D (2015) Accuracy and reproducibility of HER2 status in breast cancer using immunohistochemistry: a quality control study in Tuscany evaluating the impact of updated 2013 ASCO/CAP recommendations. Pathol Oncol Res 21:477–485. https://doi.org/10.1007/s12253-014-9852-0
doi: 10.1007/s12253-014-9852-0
pubmed: 25367072
Bonizzi G, Capra M, Cassi C, Taliento G, Pala O, Sajjadi E, Venetis K, Ivanova M, Monturano M, Renne G, Zattoni L, Guerini-Rocco E, Viale G, Orecchia R, Fusco N (2022) Biobank for translational medicine: standard operating procedures for optimal sample management. J Vis Exp. https://doi.org/10.3791/63950
doi: 10.3791/63950
pubmed: 36533819
Bonizzi G, Zattoni L, Capra M, Cassi C, Taliento G, Ivanova M, Guerini-Rocco E, Fumagalli M, Monturano M, Albini A, Viale G, Orecchia R, Fusco N (2022) Standard operating procedures for biobank in oncology. Front Mol Biosci 9:967310. https://doi.org/10.3389/fmolb.2022.967310
doi: 10.3389/fmolb.2022.967310
pubmed: 36090048
pmcid: 9459387
Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H, Taylor C, Anderson S, Gelber R, Gianni L, Jacot W, Joensuu H, Moreno-Aspitia A, Piccart M, Press M, Romond E, Slamon D, Suman V, Berry R, Boddington C, Clarke M, Davies C, Duane F, Evans V, Gay J, Gettins L, Godwin J, James S, Liu H, MacKinnon E, Mannu G, McHugh T, Morris P, Read S, Straiton E, Wang Y, Crown J, de Azambuja E, Delaloge S, Fung H, Geyer C, Spielmann M, Valagussa P, Albain K, Arriagada R, Bartlett J, Bergsten-Nordström E, Bliss J, Brain E, Carey L, Coleman R, Cuzick J, Davidson N, Del Mastro L, Di Leo A, Dignam J, Dowsett M, Ejlertsen B, Francis P, Gnant M, Goetz M, Goodwin P, Halpin-Murphy P, Hayes D, Hill C, Jagsi R, Janni W, Loibl S, Mamounas EP, Martín M, Mukai H, Nekljudova V, Norton L, Ohashi Y, Pierce L, Poortmans P, Raina V, Rea D, Regan M, Robertson J, Rutgers E, Spanic T, Sparano J, Steger G, Tang G, Toi M, Tutt A, Viale G, Wang X, Whelan T, Wilcken N, Wolmark N, Cameron D, Bergh J, Pritchard KI, Swain SM (2021) Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 22:1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6
doi: 10.1016/S1470-2045(21)00288-6
Branco FP, Machado D, Silva FF, André S, Catarino A, Madureira R, Pinto JM, Godinho JP, Simões PD, Brito M, Casa-Nova M, Moreira AR, Passos-Coelho JL (2019) Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. Am J Transl Res 11:6110–6116
pubmed: 31632579
pmcid: 6789273
Brunelli M, Nottegar A, Bogina G, Caliò A, Cima L, Eccher A, Vicentini C, Marcolini L, Scarpa A, Pedron S, Brunello E, Knuutila S, Sapino A, Marchiò C, Bria E, Molino A, Carbognin L, Tortora G, Jasani B, Miller K, Merdol I, Zanatta L, Laurino L, Wirtanen T, Zamboni G, Marconi M, Chilosi M, Manfrin E, Martignoni G, Bonetti F (2015) Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. Am J Cancer Res 5:2212–2221
pubmed: 26328251
pmcid: 4548332
Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, Fusco N, Malapelle U, Fassan M (2022) FFPE-based NGS approaches into clinical practice: the limits of glory from a pathologist viewpoint. J Pers Med 12:750. https://doi.org/10.3390/jpm12050750
doi: 10.3390/jpm12050750
pubmed: 35629172
Chung C, Yeung VTY, Wong KCW (2022) Prognostic and predictive biomarkers with therapeutic targets in breast cancer: a 2022 update on current developments, evidence, and recommendations. J Oncol Pharm Pract 0(0). https://doi.org/10.1177/10781552221119797
Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923–931. https://doi.org/10.1136/jclinpath-2014-202404
doi: 10.1136/jclinpath-2014-202404
pubmed: 25012948
De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon YCS, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS (2018) Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget 9:20617–20630. https://doi.org/10.18632/oncotarget.25041
doi: 10.18632/oncotarget.25041
pubmed: 29755676
pmcid: 5945519
de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimarães PT, Sá DDS, Simões MFE, Viana RL, Rocha FG, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Campos FAB, Sanches SM, de Lima VCC, Pondé NF (2021) HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat 190:155–163. https://doi.org/10.1007/s10549-021-06365-7
doi: 10.1007/s10549-021-06365-7
Diamantis N, Banerji U (2016) Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer 114:362–367. https://doi.org/10.1038/bjc.2015.435
doi: 10.1038/bjc.2015.435
pubmed: 26742008
pmcid: 4815767
Dileep G, Gianchandani Gyani SG (2022) Artificial intelligence in breast cancer screening and diagnosis. Cureus 14:e30318. https://doi.org/10.7759/cureus.30318
doi: 10.7759/cureus.30318
pubmed: 36381716
pmcid: 9650950
Ercolani C, Marchiò C, Di Benedetto A, Fabi A, Perracchio L, Vici P, Sperati F, Buglioni S, Arena V, Pescarmona E, Sapino A, Terrenato I, Mottolese M (2017) Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. J Exp Clin Cancer Res 36:143. https://doi.org/10.1186/s13046-017-0613-2
doi: 10.1186/s13046-017-0613-2
pubmed: 29029640
pmcid: 5640946
Ergun Y, Ucar G, Akagunduz B (2023) Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis. Cancer Treat Rev 115:102538. https://doi.org/10.1016/j.ctrv.2023.102538
doi: 10.1016/j.ctrv.2023.102538
pubmed: 36898351
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL (2022) Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 8:1–4. https://doi.org/10.1001/jamaoncol.2021.7239
doi: 10.1001/jamaoncol.2021.7239
pubmed: 35113160
pmcid: 8814969
Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell’Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE (2021) Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 11:2474–2487. https://doi.org/10.1158/2159-8290.Cd-20-1557
doi: 10.1158/2159-8290.Cd-20-1557
pubmed: 33941592
pmcid: 8598376
Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, Demeo MK, Bardia A, Dell’Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE (2021) Impact of her2 heterogeneity on treatment response of early-stage her2-positive breast cancer: phase ii neoadjuvant clinical trial of t-dm1 combined with pertuzumab. Cancer Discov 11:2474–2487. https://doi.org/10.1158/2159-8290.CD-20-1557
doi: 10.1158/2159-8290.CD-20-1557
pubmed: 33941592
pmcid: 8598376
Fusco N, Bosari S (2016) HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists. World J Gastroenterol 22:7926–7937. https://doi.org/10.3748/wjg.v22.i35.7926
doi: 10.3748/wjg.v22.i35.7926
pubmed: 27672288
pmcid: 5028807
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell’Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d’Amati G (2023) Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey. Crit Rev Oncol/Hematol 190:104103. https://doi.org/10.1016/j.critrevonc.2023.104103
doi: 10.1016/j.critrevonc.2023.104103
pubmed: 37595344
Fusco N, Malapelle U, Criscitiello C (2022) Editorial: Diagnosis and treatment of breast cancer in 2022: the rise of novel molecular biomarkers. Front Mol Biosci 9:1117323. https://doi.org/10.3389/fmolb.2022.1117323
doi: 10.3389/fmolb.2022.1117323
pubmed: 36660432
Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, Criscitiello C (2021) Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histol Histopathol 36:1235–1245. https://doi.org/10.14670/hh-18-376
Fusco N, Rizzo A, Costarelli L, Santinelli A, Cerbelli B, Scatena C, Macri E, Pietribiasi F, d’Amati G, Sapino A, Castellano I (2022) Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC). Pathologica 114:104–110. https://doi.org/10.32074/1591-951X-747
doi: 10.32074/1591-951X-747
pubmed: 35414722
pmcid: 9248246
Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, Singer CF, Roitner F, Hager C, Andel J, Hubalek M, Knauer M, Greil R (2021) Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res : BCR 23:112. https://doi.org/10.1186/s13058-021-01492-x
doi: 10.1186/s13058-021-01492-x
pubmed: 34906198
pmcid: 8670265
Giugliano F, Carnevale Schianca A, Corti C, Ivanova M, Bianco N, Dellapasqua S, Criscitiello C, Fusco N, Curigliano G, Munzone E (2023) Unlocking the resistance to anti-HER2 treatments in breast cancer: the issue of HER2 spatial distribution. Cancers (Basel) 15:1385. https://doi.org/10.3390/cancers15051385
doi: 10.3390/cancers15051385
pubmed: 36900178
Hartung ML, Baber R, Herpel E, Specht C, Brucker DP, Schoneberg A, Winter T, Nussbeck SY (2021) Harmonization of biobank education for biobank technicians: identification of learning objectives. Biotech 10:7
doi: 10.3390/biotech10020007
pubmed: 35822817
pmcid: 9336536
Hayat A, Carter EP, King HW, Ors A, Doe A, Teijeiro SA, Charrot S, Godinho S, Cutillas P, Mohammed H, Grose RP, Ficz G (2023) Low HER2 expression in normal breast epithelium enables dedifferentiation and malignant transformation via chromatin opening. Dis Model Mech 16(2): dmm049894. https://doi.org/10.1242/dmm.049894
Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, Sugino K, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H (2022) The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 29:234–241. https://doi.org/10.1007/s12282-021-01303-3
doi: 10.1007/s12282-021-01303-3
pubmed: 34622383
Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A (2019) Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 175:401–408. https://doi.org/10.1007/s10549-019-05173-4
doi: 10.1007/s10549-019-05173-4
pubmed: 30806922
Indini A, Rijavec E, Grossi F (2021) Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors. Int J Mol Sci 22:4774. https://doi.org/10.3390/ijms22094774
doi: 10.3390/ijms22094774
pubmed: 33946310
pmcid: 8125530
Jacot W, Maran-Gonzalez A, Massol O, Sorbs C, Mollevi C, Guiu S, Boissière-Michot F, Ramos J (2021) Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers. Cancers (Basel) 13:6059. https://doi.org/10.3390/cancers13236059
doi: 10.3390/cancers13236059
pubmed: 34885167
Jasani B, Huss R, Taylor CR (2021) Post-analytic phase: interpretation, scoring and reporting of biopsy results. In: Jasani B, Huss R, Taylor CR (eds) Precision cancer medicine: role of the pathologist. Springer International Publishing, Cham, pp 115–124
doi: 10.1007/978-3-030-84087-7_12
Jensen SG, Thomas PE, Christensen IJ, Balslev E, Hansen A, Høgdall E (2020) Evaluation of analytical accuracy of HER2 status in patients with breast cancer: comparison of HER2 GPA with HER2 IHC and HER2 FISH. Apmis 128:573–582. https://doi.org/10.1111/apm.13076
doi: 10.1111/apm.13076
pubmed: 32860265
Keam SJ (2020) Trastuzumab deruxtecan: first approval. Drugs 80:501–508. https://doi.org/10.1007/s40265-020-01281-4
doi: 10.1007/s40265-020-01281-4
pubmed: 32144719
Lenicek Krleza J, Honovic L, Vlasic Tanaskovic J, Podolar S, Rimac V, Jokic A (2019) Post-analytical laboratory work: national recommendations from the Working Group for Post-analytics on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb) 29:020502. https://doi.org/10.11613/bm.2019.020502
doi: 10.11613/bm.2019.020502
pubmed: 31223256
Lenicek Krleza J, Honovic L, Vlasic Tanaskovic J, Podolar S, Rimac V, Jokic A (2019) Post-analytical laboratory work: national recommendations from the Working Group for Post-analytics on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb) 29:020502–020502. https://doi.org/10.11613/BM.2019.020502
doi: 10.11613/BM.2019.020502
pubmed: 31223256
Li S, Wu J, Huang O, He J, Chen W, Li Y, Chen X, Shen K (2022) Association of molecular biomarker heterogeneity with treatment pattern and disease outcomes in multifocal or multicentric breast cancer. Front Oncol 12:833093. https://doi.org/10.3389/fonc.2022.833093
doi: 10.3389/fonc.2022.833093
pubmed: 35814416
pmcid: 9259989
Lopez G, Costanza J, Colleoni M, Fontana L, Ferrero S, Miozzo M, Fusco N (2019) Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors. Int J Mol Sci 20(3):510. https://doi.org/10.3390/ijms20030510
doi: 10.3390/ijms20030510
pubmed: 30691046
pmcid: 6386970
Loughran PA, Ross MA, St Croix CM (2022) Immunohistochemistry. Curr Protoc 2:e549. https://doi.org/10.1002/cpz1.549
doi: 10.1002/cpz1.549
pubmed: 36102926
Lucas E, Jabbar SB, Molberg K, Fang Y, Xie X-J, Blacketer S, Sahoo S (2019) Comparison of Dako Hercep test and Ventana PATHWAY Anti-HER2 (4B5) tests and their correlation with fluorescent in situ hybridization in breast carcinoma. Appl Immunohistochem Mol Morphol 27:403–409. https://doi.org/10.1097/pai.0000000000000646
doi: 10.1097/pai.0000000000000646
pubmed: 31233398
Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 72:123–135. https://doi.org/10.1016/j.semcancer.2020.02.016
doi: 10.1016/j.semcancer.2020.02.016
pubmed: 32112814
Mayr D, Heim S, Werhan C, Zeindl-Eberhart E, Kirchner T (2009) Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch 454:241–248. https://doi.org/10.1007/s00428-009-0728-8
doi: 10.1007/s00428-009-0728-8
pubmed: 19169706
Memon R, Prieto Granada CN, Harada S, Winokur T, Reddy V, Kahn AG, Siegal GP, Wei S (2022) Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression/gene amplification in breast cancer in the modern age: a single institution experience and pooled literature review study. Clin Breast Cancer 22:e123–e133. https://doi.org/10.1016/j.clbc.2021.05.004
doi: 10.1016/j.clbc.2021.05.004
pubmed: 34120846
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, Dieci MV (2021) Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7:137. https://doi.org/10.1038/s41523-021-00343-4
doi: 10.1038/s41523-021-00343-4
pubmed: 34642348
pmcid: 8511010
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa2203690
doi: 10.1056/NEJMoa2203690
pubmed: 36130006
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol : Off J Am Soc Clin Oncol 38:1887–1896. https://doi.org/10.1200/JCO.19.02318
doi: 10.1200/JCO.19.02318
Morganti S, Ivanova M, Ferraro E, Ascione L, Vivanet G, Bonizzi G, Curigliano G, Fusco N, Criscitiello C (2022) Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. Cancer Drug Resist 5:971–980. https://doi.org/10.20517/cdr.2022.55
doi: 10.20517/cdr.2022.55
pubmed: 36627895
pmcid: 9771738
Nicolò E, Boscolo Bielo L, Curigliano G, Tarantino P (2023) The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol 15:17588359231152842. https://doi.org/10.1177/17588359231152842
doi: 10.1177/17588359231152842
pubmed: 36844387
pmcid: 9943960
Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, Grogan TM (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66:313–324. https://doi.org/10.1111/pin.12407
doi: 10.1111/pin.12407
pubmed: 27061008
Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D, Howard FM (2023) Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol 9:500–510. https://doi.org/10.1001/jamaoncol.2022.7476
doi: 10.1001/jamaoncol.2022.7476
pubmed: 36821125
pmcid: 9951099
Pisapia P, L’Imperio V, Galuppini F, Sajjadi E, Russo A, Cerbelli B, Fraggetta F, d’Amati G, Troncone G, Fassan M, Fusco N, Pagni F, Malapelle U (2022) The evolving landscape of anatomic pathology. Crit Rev Oncol Hematol 178:103776. https://doi.org/10.1016/j.critrevonc.2022.103776
doi: 10.1016/j.critrevonc.2022.103776
pubmed: 35934262
Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon K, Portier B, Sredni ST, Schildhaus HU, Jasani B, Grzelinski M, Viale G (2022) Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Virchows Arch. https://doi.org/10.1007/s00428-022-03378-5
doi: 10.1007/s00428-022-03378-5
pubmed: 35970977
pmcid: 9636083
Rüschoff J, Nagelmeier I, Jasani B, Stoss O (2021) ISH-based HER2 diagnostics. Pathologe 42:62–68. https://doi.org/10.1007/s00292-020-00878-6
doi: 10.1007/s00292-020-00878-6
pubmed: 33346874
Sajjadi E, Frascarelli C, Venetis K, Bonizzi G, Ivanova M, Vago G, Guerini-Rocco E, Fusco N (2023) Computational pathology to improve biomarker testing in breast cancer: how close are we? Eur J Cancer Prev. https://doi.org/10.1097/cej.0000000000000804
doi: 10.1097/cej.0000000000000804
pubmed: 37038998
Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, Ivanova M, Fusco N (2023) Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci 3(10):1176309. https://doi.org/10.3389/fmolb.2023.1176309
doi: 10.3389/fmolb.2023.1176309
Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, Ivanova M, Fusco N (2023) Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci 10:1176309. https://doi.org/10.3389/fmolb.2023.1176309
doi: 10.3389/fmolb.2023.1176309
pubmed: 37077201
pmcid: 10106673
Sajjadi E, Venetis K, Ivanova M, Fusco N (2022) Improving HER2 testing reproducibility in HER2-low breast cancer. Drug Resist 5:882–888. https://doi.org/10.20517/cdr.2022.29
doi: 10.20517/cdr.2022.29
Sajjadi E, Venetis K, Piciotti R, Gambini D, Blundo C, Runza L, Ferrero S, Guerini-Rocco E, Fusco N (2021) Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. BMC Cancer 21:1152. https://doi.org/10.1186/s12885-021-08889-z
doi: 10.1186/s12885-021-08889-z
pubmed: 34706703
pmcid: 8555186
Sapino A, Goia M, Recupero D, Marchio C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 21(3):129. https://doi.org/10.3389/fonc.2013.00129
doi: 10.3389/fonc.2013.00129
Sapino A, Goia M, Recupero D, Marchiò C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 3:129–129. https://doi.org/10.3389/fonc.2013.00129
doi: 10.3389/fonc.2013.00129
pubmed: 23734345
pmcid: 3659312
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7:1. https://doi.org/10.1038/s41523-020-00208-2
doi: 10.1038/s41523-020-00208-2
pubmed: 33397968
pmcid: 7782714
Schrohl AS, Pedersen HC, Jensen SS, Nielsen SL, Brünner N (2011) Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 59:975–983. https://doi.org/10.1111/j.1365-2559.2011.04034.x
doi: 10.1111/j.1365-2559.2011.04034.x
pubmed: 22092409
pmcid: 3263426
Scott M, Vandenberghe ME, Scorer P, Boothman A-M, Barker C (2021) Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. J Clin Oncol 39:1021–1021. https://doi.org/10.1200/JCO.2021.39.15_suppl.1021
doi: 10.1200/JCO.2021.39.15_suppl.1021
Sun H, Chen H, Crespo J, Tang G, Robinson M, Lim B, Şahin AA (2021) Clinicopathological features of breast cancer with polysomy 17 and its response to neoadjuvant chemotherapy. Eur J Breast Health 17:128–136. https://doi.org/10.4274/ejbh.galenos.2021.2021-2-9
doi: 10.4274/ejbh.galenos.2021.2021-2-9
pubmed: 33870112
pmcid: 8025723
Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G (2022) Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 163:35–43. https://doi.org/10.1016/j.ejca.2021.12.022
doi: 10.1016/j.ejca.2021.12.022
pubmed: 35032815
Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2022.2286
doi: 10.1001/jamaoncol.2022.2286
pubmed: 35737367
pmcid: 9227690
Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano G (2023) ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 34:645–659. https://doi.org/10.1016/j.annonc.2023.05.008
doi: 10.1016/j.annonc.2023.05.008
pubmed: 37269905
Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu EB, Swanson PE, Taylor CR, Vyberg M (2014) Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Panel. Appl Immunohistochem Mol Morphol 22(4):241–52. https://doi.org/10.3390/ijms20030510
doi: 10.3390/ijms20030510
pubmed: 24714041
pmcid: 4206554
Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, Curigliano G, Criscitiello C, Fusco N (2022) HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 5(9). https://doi.org/10.3389/fmolb.2022.834651
Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C, Fusco N (2021) Breast cancer with bone metastasis: molecular insights and clinical management. Cells 10(6):1377. https://doi.org/10.3390/cells10061377
doi: 10.3390/cells10061377
pubmed: 34199522
pmcid: 8229615
Viale G, Fusco N (2021) Pathology after neoadjuvant treatment — how to assess residual disease. Breast. https://doi.org/10.1016/j.breast.2021.11.009
doi: 10.1016/j.breast.2021.11.009
pubmed: 34810049
pmcid: 9097800
Viale G, Niikura N, Tokunaga E, Aleynikova O, Hayashi N, Sohn J, O’Brien C, Higgins G, Varghese D, James GD, Moh A, Scotto N (2022) Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics. J Clin Oncol 40:1087–1087. https://doi.org/10.1200/JCO.2022.40.16_suppl.1087
doi: 10.1200/JCO.2022.40.16_suppl.1087
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/jco.2013.50.9984
doi: 10.1200/jco.2013.50.9984
pubmed: 24101045
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/jco.2018.77.8738
doi: 10.1200/jco.2018.77.8738
pubmed: 29846122
Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M (2018) HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract 14:437–441. https://doi.org/10.1200/jop.18.00206
doi: 10.1200/jop.18.00206
pubmed: 29920138
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984
doi: 10.1200/JCO.2013.50.9984
pubmed: 24101045
Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH (2023) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2023-0950-SA
doi: 10.5858/arpa.2023-0950-SA
pubmed: 37303228
Yildiz-Aktas IZ, Dabbs DJ, Bhargava R (2012) The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 25:1098–1105. https://doi.org/10.1038/modpathol.2012.59
doi: 10.1038/modpathol.2012.59
pubmed: 22460807
Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG (2022) HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. https://doi.org/10.1038/s41379-022-01019-5
doi: 10.1038/s41379-022-01019-5
pubmed: 36088477
pmcid: 9926946
Zhang H, Katerji H, Turner BM, Hicks DG (2021) HER2-low breast cancers: new opportunities and challenges. Am J Clin Pathol 157(3):328–336. https://doi.org/10.1093/ajcp/aqab117
doi: 10.1093/ajcp/aqab117
Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG (2020) Applying the new guidelines of HER2 testing in breast cancer. Curr Oncol Rep 22:51. https://doi.org/10.1007/s11912-020-0901-4
doi: 10.1007/s11912-020-0901-4
pubmed: 32346807